You are here: Home » News-CM » Equities » Hot Pursuit
Business Standard

Cadila Healthcare gets USFDA nod for droxidopa capsules

Capital Market 

The drug maker has received final approval from the drug regulatory body, United States Food & Drug Administration (USFDA) to market droxidopa capsules, 100 mg, 200 mg, and 300 mg (US RLD: Northera Capsules).

Droxidopa capsules works by constricting (narrowing) the blood vessels and increasing blood pressure. It is used to treat low blood pressure that causes severe dizziness or a light-headed feeling. It is indicated for use in people with conditions of the nervous system that can cause low blood pressure (such as Parkinson's disease, multiple system atrophy, autonomic failure, and others).

The drug will be manufactured at the Group's formulation manufacturing facility at the SEZ, Ahmedabad (Gujarat). The group now has 312 approvals and has so far filed over 400 ANDAs since the commencement of the filing process in FY 2003-04. The announcement was made during market hours today, 19 February 2021.

Cadila Healthcare reported 40.6% rise in consolidated net profit to Rs 512.50 crore on a 6.2% rise in net sales to Rs 3,753.70 crore in Q3 FY21 over Q3 FY20.

Shares of Cadila Healthcare lost 1.67% to Rs 459.70 on BSE. Cadila Healthcare is a global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies.

Powered by Capital Market - Live News

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Fri, February 19 2021. 11:42 IST